| 000 | 01865 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513120405.0 | ||
| 264 | 0 | _c19970616 | |
| 008 | 199706s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.1997.15.5.1965 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGordon, A N | |
| 245 | 0 | 0 |
_aPhase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cMay 1997 |
||
| 300 |
_a1965-73 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aCA-125 Antigen _xblood |
| 650 | 0 | 4 |
_aCarcinoma _xblood |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFilgrastim |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeutropenia _xchemically induced |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xblood |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 |
_aPeripheral Nervous System Diseases _xchemically induced |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 700 | 1 | _aStringer, C A | |
| 700 | 1 | _aMatthews, C M | |
| 700 | 1 | _aWillis, D L | |
| 700 | 1 | _aNemunaitis, J | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 15 _gno. 5 _gp. 1965-73 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1997.15.5.1965 _zAvailable from publisher's website |
| 999 |
_c9145416 _d9145416 |
||